Takeaways Once-monthly MariTide led to up to 17.5% weight loss in 52 weeks, with minimal regain after stopping treatment. The drug combines GLP-1 and glucagon receptor activity, offering fat burn and appetite suppression…
Takeaways Emerging GPCR-targeted therapies could offer oral, appetite-modifying weight-loss options with fewer GI side effects. GSBR-1290 shows real human efficacy (~5–7% weight loss) and convenience, while BRP highlights non-incretin, central-acting alternatives in preclinical…
Takeaways Controlled mitochondrial uncouplers like HU6 are in early human trials and show promise for reducing liver fat and body adiposity while preserving lean mass. Organ-targeted and prodrug delivery systems enhance safety by…
Takeaways Dual‑pathway therapies deliver stronger, longer-lasting fat loss while preserving lean mass. AI‑guided dosing promises smarter personalization, improving adherence and real‑world outcomes. The oral and injectable co‑agonist amycretin marks a breakthrough in obesity…
Ecnoglutide (XW003): The Next-Generation GLP-1 Analog Redefining Weight-Management Therapy For clinics developing truly integrated medical weight loss programs, a once-weekly GLP-1 analog called ecnoglutide is emerging as the most advanced “biased-signaling” option yet.…
Takeaways Gene-editing therapies targeting obesity now enter first-in-human trials, aiming to deliver one-time, lasting results. Programs like Verve-102 and MC4R editors focus on reducing fat while preserving or improving metabolic health. These curative…
Takeaways Dual-Path Weight Loss cuts fat dramatically while preserving lean muscle, solving the key drawback of GLP-1 monotherapy. Phase 2b BELIEVE data show 22 % total-weight loss with 93 % fat reduction; a…
Takeaways Oral GLP-1 receptor agonists offer a needle-free alternative that can improve adherence and expand access to obesity treatment. Medications like semaglutide and orforglipron work by reducing appetite, slowing digestion, and boosting insulin…
Takeaways CRISPR offers precise gene editing methods that enhance metabolic efficiency by targeting specific genes involved in fat regulation and energy expenditure. Emerging preclinical and early trial data indicate that CRISPR-based interventions could…
Jessica DeBenedetto, a 43-year-old woman battling prediabetes since her 20s, recently started using compounded tirzepatide, a less expensive, generic alternative to Eli Lilly’s Zepbound. For her, the drug felt like a life-changer, especially…